Delivering advanced therapies: the big pharma approach.

Area of Science:

• Biotechnology
• Genetics
• Pharmacology

Background:

• Cell and gene therapy (CGT) has undergone two decades of development, with recent clinical successes highlighting its potential.
• CGT represents a new frontier in personalized medicine, complementing existing small molecule and biopharmaceutical treatments.

Purpose of the Study:

• To outline the critical role of large pharmaceutical companies in the industrialization of CGT.
• To identify key considerations for the successful commercialization and widespread adoption of CGT.

Main Methods:

• Analysis of the current landscape of cell and gene therapy development.
• Identification of strategic imperatives for pharmaceutical industry involvement.

Main Results:

• Big pharma can accelerate CGT by targeting diseases with high unmet needs and strong genetic links.
• Investment in robust manufacturing, supply chain solutions, and regulatory engagement is essential for reproducible, cost-effective therapies.

Conclusions:

• Successful commercialization requires proactive regulatory engagement and a deep understanding of the patient journey.
• Sustainable adoption hinges on establishing product pricing acceptable to prescribers, payers, and patients.